X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
The goals of this protocol are 1) to investigate the safety and tolerability of X4P-001 in
combination with Keytruda® (pembrolizumab) in patients with advanced melanoma, and 2) to
assess serial biopsies of melanoma tumor lesions obtained throughout the study for
inflammatory and tumor cell infiltrates. After completion of study treatment, participants
with resectable disease will undergo surgery, unresectable participants may continue on
pembrolizumab as standard of care.